Medtronic achieved global revenue of almost $9bn in Q2 FY26, with its cardiovascular portfolio contributing $3.44bn.

The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

The PFA-SHAM trial and MANIFEST-US registry support the efficacy and safety of the increasingly used ablation modality.

Dr. Mark Shen performed the surgery using a new system called “Affera Mapping and Ablation” to treat atrial fibrillation.

No significant difference seen in composite outcome of stroke, systemic embolism, new covert embolic stroke.

Medtronic posted a slate of strong quarterly financial results this morning, with its cardiovascular device portfolio pushing ...

Pulsed field ablation sales grew by more than 300% in the second quarter for the company’s fiscal year 2026, amid mounting ...

The future of heart health is on showcase here in the Quad Cities. Two medical ‘firsts’ were announced last week. A new tool ...

Hamilton Medical Center pioneers use of Medtronic Sphere-9 ablation tech, boosting precision, safety, and recovery for heart ...

Medtronic plc posted solid fiscal year second-quarter results led by the cardiovascular business with 9.3% growth. The Affera Sphere-9 pulsed field ablation system tripled the company’s sales in the ...

A composite of stroke, systemic embolism, or new covert embolic stroke, occurred in 5 and 9 patients in the rivaroxaban and aspirin groups, respectively.

About VIVO ™ Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, ...